Drug intelligence / Profile preview

IL-13-K

Development stage: Preclinical
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intravenous, Inhalation

Overview

IL-13-K is a conjugate vaccine under development for the treatment of allergic asthma. It is designed to induce an immune response against human interleukin-13 (IL-13), a type 2 cytokine implicated in allergic asthma pathogenesis. The vaccine aims to neutralize IL-13, thereby reducing elevated IgE levels, airway hyperresponsiveness (AHR), eosinophilia, and mucus production. The development of IL-13-K is part of a broader strategy exploring dual IL-4/IL-13 vaccination for long-term, cost-effective therapeutic management of allergic asthma, as demonstrated in mouse models.

Targets

IL-13 (Interleukin-13)

Beyond the preview

Go deeper on IL-13-K.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IL-13-K.

Explore the full profile